Vivos Therapeutics完成对Sod Sciences股权的收购,并取得假性缺氧检测50%权益,有望通过Aha渠道触达逾32.5万名新患者
Vivos Therapeutics完成对Sod Sciences股权的收购,并取得假性缺氧检测50%权益,有望通过Aha渠道触达逾32.5万名新患者
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.